LRRC32 Antikörper (PE)

Produktnummer ABIN2662727

Produktdetails anti-LRRC32 Antikörper (PE)

Target: LRRC32 (Leucine Rich Repeat Containing 32 (LRRC32))

Reaktivität: Maus

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser LRRC32 Antikörper ist konjugiert mit PE

Applikation: Flow Cytometry (FACS), Immunohistochemistry (IHC)

Aufreinigung: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Klon: F011-5

Isotyp: IgG2a kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu LRRC32

Target: LRRC32 (Leucine Rich Repeat Containing 32 (LRRC32))

Andere Bezeichnung: GARP (LRRC32 Produkte)

Synonyme: D11S833E antikoerper, GARP antikoerper, AI426318 antikoerper, D11S833Eh antikoerper, D7H11S833E antikoerper, EG434215 antikoerper, Garp antikoerper, leucine rich repeat containing 32 antikoerper, LRRC32 antikoerper, Lrrc32 antikoerper

Hintergrund: Glycoprotein A Repetitions Predominant (GARP), also known as leucine rich repeat containing protein 32 (LRC32), is a 80 kD type I membrane glycoprotein with 20 leucine rich repeats in the extracellular portion of the protein. GARP was found on the surface of megakaryocytes, platelets, and activated Tregs. It serves as a receptor for latent TGF-β. Recent evidence suggests that GARP may play a role in controlling suppressor function of Tregs. A mutation in GARP has been reported in a large Samaritan kindred with Usher syndrome type 1. In addition, it has been found that GARP mRNA is highly amplified in different tumors, which indicates that tumor cells may use GARP to express TGF-β or to capture TGF-β from their surroundings, resulting in local suppression of anti-tumor immune responses or the induction of Tregs.

Pathways: Activated T Cell Proliferation